PMID- 17161912
OWN - NLM
STAT- MEDLINE
DCOM- 20070313
LR  - 20211203
IS  - 0305-7372 (Print)
IS  - 0305-7372 (Linking)
VI  - 33
IP  - 1
DP  - 2007 Feb
TI  - Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma.
PG  - 78-84
AB  - The mammalian target of rapamycin (mTOR) is a large and highly conserved kinase 
      that integrates growth factor stimulation, energy and nutrient availability to 
      modulate translation of proteins responsible for cellular growth and 
      proliferation. Its importance in malignant cells provides strong rationale for 
      the development of mTOR inhibitors (mTORi) in a broad variety of solid tumors and 
      hematological malignancies. However several questions regarding mTOR biology and 
      its interaction with pharmacological inhibitors remain unanswered and are 
      relevant for further development of this novel family of cancer drugs. 
      Nevertheless, mTORi have demonstrated activity in lymphoma cells either alone or 
      in combination with cytotoxic agents. The most promising results have been seen 
      in mantle cell lymphoma (MCL), likely because of its dependence on Cyclin D, the 
      translation of which is largely regulated by mTOR activity. The currently 
      knowledge of mTOR biology will here be reviewed along with the status of clinical 
      development of mTORi in non-Hodgkin's lymphomas.
FAU - Costa, Luciano Jose
AU  - Costa LJ
AD  - Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, 
      USA. costa.luciano@mayo.edu
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20061211
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 136601-57-5 (Cyclin D1)
RN  - 624KN6GM2T (temsirolimus)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antibiotics, Antineoplastic/*pharmacology/therapeutic use
MH  - Cyclin D1/drug effects
MH  - Humans
MH  - Lymphoma, Mantle-Cell/drug therapy
MH  - Lymphoma, Non-Hodgkin/*drug therapy
MH  - Protein Kinase Inhibitors/*pharmacology/therapeutic use
MH  - Protein Kinases/*drug effects/metabolism
MH  - Sirolimus/analogs & derivatives/*pharmacology/therapeutic use
MH  - TOR Serine-Threonine Kinases
RF  - 54
EDAT- 2006/12/13 09:00
MHDA- 2007/03/14 09:00
CRDT- 2006/12/13 09:00
PHST- 2006/08/24 00:00 [received]
PHST- 2006/10/18 00:00 [revised]
PHST- 2006/10/18 00:00 [accepted]
PHST- 2006/12/13 09:00 [pubmed]
PHST- 2007/03/14 09:00 [medline]
PHST- 2006/12/13 09:00 [entrez]
AID - S0305-7372(06)00205-2 [pii]
AID - 10.1016/j.ctrv.2006.10.004 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2007 Feb;33(1):78-84. doi: 10.1016/j.ctrv.2006.10.004. Epub 
      2006 Dec 11.